The addition of the potent triple angiokinase inhibitor nintedanib to a standard chemotherapeutic regimen consisting of gemcitabine and cisplatin generated survival benefit in patients with locally advanced muscle invasive bladder cancer (MIBC), according to the results of the NEO-BLADE* trial presented at ASCO GU 2020. However, the study failed to demonstrate improvement in the primary endpoint of pathologic complete response (CR).
The recently published phase III POUT* trial demonstrated that adjuvant gemcitabine-platinum chemotherapy after nephroureterectomy boosts disease free-survival (DFS) in patients with locally advanced upper urinary tract urothelial carcinoma (UTUC).
The use of sipuleucel-T significantly prolongs overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), regardless of treatment setting, based on real-world data presented at ASCO GU 2020.
Early rehabilitative measures such as preoperative pelvic floor muscle exercise (PFME) may promote early recovery of urinary continence following holmium laser enucleation of the prostate (HoLEP) for benign prostatic hyperplasia, a study has shown.
A combination therapy of enfortumab vedotin and pembrolizumab shows promising activity, with rapid and durable responses in the first-line setting for patients with metastatic urothelial carcinoma (mUC) ineligible to receive cisplatin, according to updates from the EV-103* study presented at GUCS 2020.
Robot-assisted radical cystectomy (RARC) is comparable to open radical cystectomy (ORC) in terms of recurrence and 3-year overall (OS) and progression-free survival (PFS), highlighting the oncologic equivalence of these two approaches, according to the results of the Randomized Open versus Robotic Cystectomy (RAZOR) trial.
The novel polyethylene glycol (PEG)-coated collagen patch was safe and feasible to use for achieving intraoperative haemostasis in patients undergoing deceased-donor renal transplant (DDRT), a study has shown.
Patients with previously treated advanced or metastatic clear cell renal cell carcinoma (RCC) appear to derive greater overall survival (OS) benefit with nivolumab compared with everolimus, according to final results of the phase III CheckMate 025* trial presented at ASCO GU 2020.
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.